Alnylam Q1 2022 Earnings Report
Key Takeaways
Alnylam Pharmaceuticals reported its Q1 2022 financial results, with global net product revenues of $186.872 million. The company experienced a GAAP net loss of $240.341 million, or $2.00 per share.
Achieved global net product revenues of $187 million for ONPATTRO, GIVLAARI, and OXLUMO.
Reported positive 18-Month results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy
Announced 3-Month Extension of Review Period for New Drug Application for Vutrisiran due to Amendment to Address Pending Inspection Classification at Third-Party Secondary Packaging and Labeling Facility
Decreased 2022 Guidance Range for Combined Net Product Revenues from $900 Million – $1 Billion to $870 – $930 Million
Alnylam
Alnylam
Alnylam Revenue by Segment
Forward Guidance
Alnylam updated its full year 2022 financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income